Standard Biotools (LAB) Non-Current Deffered Revenue (2010 - 2026)

Standard Biotools (LAB) has 17 years of Non-Current Deffered Revenue data on file, last reported at $3.0 million in Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $3.0 million, down 90.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 million (down 90.74% YoY), and the FY2025 annual result was $3.5 million, down 89.28% from the prior year.
• Non-Current Deffered Revenue declined to $3.0 million in Q1 2026 per LAB's latest filing, from $3.5 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $33.9 million in Q1 2024 and troughed at $2.4 million in Q3 2025.
• A 5-year average of $12.4 million and a median of $3.8 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue soared 840.76% in 2024, then tumbled 92.76% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $3.8 million in 2022, then decreased by 7.76% to $3.5 million in 2023, then jumped by 828.24% to $32.7 million in 2024, then sank by 89.28% to $3.5 million in 2025, then dropped by 13.99% to $3.0 million in 2026.
• Business Quant data shows LAB's Non-Current Deffered Revenue at $3.0 million in Q1 2026, $3.5 million in Q4 2025, and $2.4 million in Q3 2025.